Cash and cash equivalents at the end of the third quarter were $11.1 million, compared to $31.2 million on December 31, 2022.
•
Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.
•
Research and development expenses for the quarter ended September 30, 2023 were $4.2 million compared to $6.0 million for the same period in 2022. The $1.8 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors.
•
General and administrative expenses for the quarter ended September 30, 2023 were $2.4 million compared to $2.8 million for the same period in 2022. The decrease was primarily due to a decrease in consulting and professional expenses and personnel costs.
Year-to-Date
•
Net cash used in operations for the nine months ended September 30, 2023 was $21.2 million.
•
Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.
Research and development expenses for the nine months ended September 30, 2023 were $13.3 million compared to $16.7 million for the same period in 2022. The $3.4 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors, partially offset by an increase in facilities expenses.
•
General and administrative expenses for the nine months ended September 30, 2023 were $8.3 million compared to $9.0 million for the same period in 2022. The $0.7 million decrease was primarily due to a decrease in consulting and professional expenses.
Recent TPST News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/13/2024 08:54:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:29:58 PM
- Tempest Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:29:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:25:05 PM
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/26/2024 08:05:17 PM
- Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Tempest Reports Year End 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/19/2024 08:25:36 PM
- Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Tempest to Present at the 44th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:49:42 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:12:13 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/08/2024 10:41:56 PM
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/02/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:41:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:40:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:39:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:38:19 PM
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/05/2024 09:05:00 PM
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/01/2023 09:15:51 PM
- Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 01:00:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 11/17/2023 09:46:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 11/17/2023 09:45:26 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 11/17/2023 09:44:57 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM